Purpose: To investigate the effect of intravitreal triamcinolone acetonide injection on the resolution of subretinal fluid (SRF), and its correlation with visual outcome after scleral buckle (SB) surgery. Methods: A prospective consecutive case series was conducted in patients who underwent SB surgery for macula-off rhegmatogenous retinal detachment (RRD) at Farabi Eye Hospital from February 1, 2012 to August 30, 2013. Exclusion criteria included previous ocular surgery (e.g. primary surgical failure) except cataract surgery, recurrent retinal detachment, macular hole, epiretinal membrane, proliferative vitreoretinopathy grade C, history of trauma, other retinal diseases, and diabetes mellitus. Patients were assigned to two groups. In group 1, patients received 2 mg of intravitreal triamcinolone acetonide injection at the end of surgery while patients in group 2 received intravitreal balanced saline solution for balancing the intraocular pressure (IOP). Patients were followed up at 1 day, 1 week, 1 month, 2 months and 3 months after the surgery by best-corrected visual acuity (BCVA), slitlamp examination, indirect ophthalmoscopy and optical coherence tomography (OCT). OCT (Heidelberg Engineering, Heidelberg, Germany) was used at all visits except day 1 after the surgery. Student's t test and χ2 tests were used for comparisons; p value ≤0.05 was considered significant. Results: Sixty-two eyes of 62 patients were enrolled in the study. There were 33 male patients (53%) and 29 female patients (47%). The average age was 43.8 years (18-72 years). The mean duration of symptoms was 34.7 ± 46.8 days. There were 29 eyes in group 1 and 33 eyes in group 2. Twelve weeks after the operation, 25 patients (40%) had SRF beneath the macula, but there was no significant difference (p = 0.24, χ2 test) between the two groups. Improvement in BCVA in both groups was statistically significant (p ≤ 0.001) but did not differ between the two groups (p = 0.09) apart from week 12, in which the improvement in group 1 was significantly higher (p = 0.03). The incidence of cystoid macular edema did not differ in a statistically significant way between the groups (p = 0.19). IOP in 4 (15%) patients in group 1 rose above 21 mm Hg but responded quickly to 2 weeks of topical antiglaucoma medication. There was no cataract progression in either group. There was no correlation between the incidence of persistent SRF and the extent of detachment in both groups (p = 0.83). There was no surgical failure or redetachment in either group during the study period. Conclusion: Single-dose intravitreal triamcinolone may increase the final BCVA in macula-off RRD patients despite persistent SRF, suggesting the anti-inflammatory role of this drug.

Keywords:
Intravitreal injection, Triamcinolone acetonide, Scleral buckling, Subretinal fluid, Visual acuity, Optical coherence tomography
1.
Woo SJ, Lee KM, Chung H, Park KH: Photoreceptor disruption related to persistent submacular fluid after successful scleral buckle surgery. Korean J Ophthalmol 2011;25:380-386.
2.
Hagimura N, Iida T, Suto K, Kishi S: Persistent foveal retinal detachment after successful rhegmatogenous retinal detachment surgery. Am J Ophthalmol 2002;133:516-520.
3.
Tunc M, Lahey JM, Kearney JJ, Lewis JM, Francis R: Cystoid macular oedema following pneumatic retinopexy vs scleral buckling. Eye 2007;21:831-834.
4.
Wolfensberger TJ: Foveal reattachment after macula-off retinal detachment occurs faster after vitrectomy than after buckle surgery. Ophthalmology 2004;111:1340-1343.
5.
Benson SE, Schlottmann PG, Bunce C, Xing W, Charteris DG: Optical coherence tomography analysis of the macula after scleral buckle surgery for retinal detachment. Ophthalmology 2007;114:108-112.
6.
Lobes LA Jr, Grand MG: Incidence of cystoid macular edema following scleral buckling procedure. Arch Ophthalmol 1980;98:1230-1232.
7.
Hagimura N, Suto K, Iida T, Kishi S: Optical coherence tomography of the neurosensory retina in rhegmatogenous retinal detachment. Am J Ophthalmol 2000;129:186-190.
8.
Theodossiadis PG, Georgalas IG, Emfietzoglou J, et al: Optical coherence tomography findings in the macula after treatment of rhegmatogenous retinal detachment with spared macula preoperatively. Retina 2003;23:69-75.
9.
Wolfensberger TJ, Gonvers M: Optical coherence tomography in the evaluation of incomplete visual acuity recovery after macula-off retinal detachments. Graefes Arch Clin Exp Ophthalmol 2002;240:85-89.
10.
Kaga T, Fonesca RA, Dantes MA, Yannuzi LA, Spaide RF: Optical coherence tomography of bleb-like subretinal lesions after retinal reattachment surgery. Am J Ophthalmol 2001;132:120-121.
11.
Benson SE, Ratcliffe S, Van Raders P, et al: A randomised comparison of parecoxib/valdecoxib and placebo for the prevention of cystoid macular edema after scleral buckling surgery. Retina 2009;29:387-394.
12.
Wu JS, Lin CH, Hwang JF, Chen SN: Influence of systemic steroids on subretinal fluid after scleral buckle surgery for macula-off retinal detachment. Retina 2011;31:99-104.
13.
Abouzeid H, Becker K, Holz FG, Wolfensberger TJ: Submacular fluid after encircling buckle surgery for inferior macula-off retinal detachment in young patients. Acta Ophthalmol 2009;87:96-99.
14.
Kang SW, Kim JH, Shin WJ, Kim JI: Subretinal fluid bleb after successful scleral buckling and cryotherapy for retinal detachment. Am J Ophthalmol 2008;146:205-210.
15.
Koinzer S, Elsner H, Klatt C, et al: Selective retina therapy (SRT) of chronic subfoveal fluid after surgery of rhegmatogenous retinal detachment: three case reports. Graefes Arch Clin Exp Ophthalmol 2008;246:1373-1378.
16.
Weene LE: Cystoid macular edema after scleral buckling responsive to acetazolamide. Ann Ophthalmol 1992;24:423-424.
17.
Ackerman AL, Topilow HW: A reduced incidence of cystoid macular edema following retinal detachment surgery using diathermy. Ophthalmology 1985;92:1092-1095.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.